https://www.selleckchem.com/pr....oducts/Verteporfin(V
Chronic cough is a highly problematic symptom for patients with idiopathic pulmonary fibrosis (IPF); limited therapeutic options are available. We evaluated gefapixant, a P2X3 receptor antagonist, for the treatment of chronic cough in IPF. This randomized, double-blind, placebo-controlled, crossover study included subjects with IPF. Sequence A included gefapixant 50mg BID (period 1; 14days) followed by placebo (period 2; 14days); sequence B had the opposite sequence of treatments. This regimen was specified in a protocol a
Like
Comment
Share
